{
    "ticker": "ATCH",
    "name": "Athenex, Inc.",
    "description": "Athenex, Inc. is a global biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for the treatment of cancer. Founded in 2003, Athenex operates with the mission of improving the lives of cancer patients through innovative drug development and advanced therapeutic technologies. The company's core focus is on bringing to market therapies that can enhance the efficacy and safety of cancer treatment. Athenex has developed a unique platform that integrates drug development with advanced manufacturing capabilities, which allows for the production of high-quality, cost-effective therapies. Athenex's lead product candidates, such as KUR-502 and Athenex\u2019s oral paclitaxel, aim to improve patient outcomes in various cancer types, including breast and gastric cancers. The company is also committed to advancing its research in combination therapies and personalized medicine, striving to address the unmet needs of cancer patients. With a strong pipeline of clinical-stage assets, Athenex is at the forefront of cancer treatment innovation and is actively collaborating with key partners in the pharmaceutical industry to expedite the delivery of new therapies to patients.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "Buffalo, New York, USA",
    "founded": "2003",
    "website": "https://www.athenex.com",
    "ceo": "Dr. Johnson Lau",
    "social_media": {
        "twitter": "https://twitter.com/AthenexInc",
        "linkedin": "https://www.linkedin.com/company/athenex/"
    },
    "investor_relations": "https://ir.athenex.com",
    "key_executives": [
        {
            "name": "Dr. Johnson Lau",
            "position": "CEO"
        },
        {
            "name": "Dr. Wei Zhan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Products",
            "products": [
                "KUR-502",
                "Oral Paclitaxel"
            ]
        }
    ],
    "seo": {
        "meta_title": "Athenex, Inc. | Innovating Cancer Treatment",
        "meta_description": "Explore Athenex, Inc., a biopharmaceutical company focused on developing innovative therapeutics for cancer treatment. Learn about our mission and cutting-edge therapies.",
        "keywords": [
            "Athenex",
            "Biopharmaceutical",
            "Cancer Treatment",
            "Innovative Therapies",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What does Athenex focus on?",
            "answer": "Athenex focuses on developing and commercializing innovative therapeutics for cancer treatment."
        },
        {
            "question": "Who is the CEO of Athenex?",
            "answer": "Dr. Johnson Lau is the CEO of Athenex, Inc."
        },
        {
            "question": "Where is Athenex headquartered?",
            "answer": "Athenex is headquartered in Buffalo, New York, USA."
        },
        {
            "question": "What are Athenex's main products?",
            "answer": "Athenex's main products include KUR-502 and Oral Paclitaxel."
        },
        {
            "question": "When was Athenex founded?",
            "answer": "Athenex was founded in 2003."
        }
    ],
    "competitors": [
        "MRK",
        "BMY",
        "AMGN",
        "GILD"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "ABBV",
        "NVS"
    ]
}